Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotech advancing novel therapies for fibro-inflammatory diseases. This news hub provides investors and researchers with essential updates on nebokitug (CM-101), the company's lead monoclonal antibody targeting CCL24 in conditions like primary sclerosing cholangitis (PSC) and systemic sclerosis.
Access timely reports on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes verified updates from Phase 2/3 trials, FDA/EMA designations, and scientific conference presentations. Key focus areas span biomarker validation, trial enrollment status, and intellectual property developments.
This resource serves as your central source for tracking Chemomab's progress in addressing high-need rare diseases. Bookmark this page for direct access to primary documents including SEC filings, peer-reviewed data publications, and official press releases. Check regularly for updates on the upcoming Phase 3 PSC trial and expansion into new fibrotic disease indications.
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) announced the appointment of David M. Weiner, MD, as Interim Chief Medical Officer, effective immediately. He replaces Dr. Arnon Aharon, who will remain for a 60-day transition period. Dr. Weiner brings over 25 years of biopharmaceutical experience and has held senior roles at various biotech companies. He aims to advance Chemomab's clinical programs, particularly for CM-101, a monoclonal antibody in Phase 2 trials targeting fibrotic diseases. The company acknowledges Dr. Aharon's contributions to its clinical advancements.
Chemomab Therapeutics (CMMB) announced its third-quarter financial results for 2021, revealing a significant cash position of $64.3 million, which is expected to fund operations until mid-2023. The company reported a net loss of $3.0 million, or ($0.01) per share, compared to a loss of $1.2 million in the previous year. Key updates included advancements in clinical trials for CM-101 aimed at treating fibrotic diseases and the appointment of Donald Marvin as CFO. Upcoming data readouts from ongoing Phase 2 trials are anticipated in 2022, suggesting potential growth for Chemomab's pipeline.
Chemomab Therapeutics (Nasdaq: CMMB) announced a poster presentation at The Liver Meeting 2021, showcasing its research on CCL24's role in Primary Sclerosing Cholangitis (PSC). The study highlights the high expression of CCL24 in PSC liver biopsies and the efficacy of the monoclonal antibody CM-101 in reducing liver injury in preclinical models. CM-101 is currently in Phase 2 trials targeting PSC and other fibrotic diseases. The company's advancements provide promising insights into potential treatment avenues.
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech firm, will host a presentation and participate in 1-on-1 investor meetings at Stifel's 2021 Virtual Healthcare Conference on November 15, 2021, at 8:00 AM ET. Dr. Dale Pfost (CEO) and Dr. Adi Mor (CSO) will present. Chemomab specializes in innovative therapeutics for fibrotic and inflammatory diseases, focusing on CM-101, an antibody targeting CCL24. This candidate shows promise in treating severe fibrotic diseases and is currently in Phase 2 trials.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) has appointed Donald R. Marvin as the new Chief Financial Officer, Executive Vice President, and Chief Operating Officer. With over 35 years of experience in corporate finance and operations, Mr. Marvin aims to utilize his expertise to advance Chemomab's clinical programs. The company is focused on innovative therapeutics for fibrotic and inflammatory diseases, notably its drug CM-101, which is currently in Phase 2 clinical trials for various conditions. The leadership change is seen as a strategic move to enhance Chemomab's growth and operational efficiency.
Chemomab Therapeutics (Nasdaq: CMMB) announced a webinar featuring Dr. Dinesh Khanna, an expert in systemic sclerosis (SSc), on November 3, 2021. The discussion will cover the treatment landscape and clinical utility of CM-101, a monoclonal antibody targeting CCL24. CM-101 is currently being evaluated in Phase 2 trials for various fibrotic conditions, including SSc. As SSc lacks approved disease-modifying treatments, Chemomab aims to address this unmet medical need with its innovative therapies.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced a collaboration with Leeds University to study CCL24's role in vascular damage related to systemic sclerosis (SSc), a severe autoimmune condition. Led by Professor Francesco Del Galdo, this partnership aims to deepen the understanding of CCL24's contribution to SSc pathology. Chemomab plans to assess its CCL24-neutralizing monoclonal antibody, CM-101, in a Phase 2 trial in SSc patients starting early next year, building on existing mechanistic data.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) has appointed Dale R. Pfost, PhD, as its new Chief Executive Officer. He will replace co-founder Adi Mor, who will continue as Chief Scientific Officer. Dr. Pfost brings over 30 years of experience in the biotech industry, having successfully led six companies and overseen several public offerings. His appointment reflects a strategic expansion of the senior management team as Chemomab progresses with two ongoing Phase 2 studies and prepares for a third trial. Shareholder approval for his role is expected in Q4 2021.
Chemomab Therapeutics, Ltd (Nasdaq: CMMB), a clinical-stage biotech firm, will attend several investor conferences in September 2021. Key events include the Citi 16th Annual BioPharma Virtual Conference from September 8-10, the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, and the Oppenheimer Fall Healthcare Summit on September 22. The company's lead product, CM-101, a monoclonal antibody targeting fibrosis, is currently in Phase 2 trials for primary sclerosing cholangitis and systemic sclerosis. Further information can be found on their website.
Chemomab Therapeutics Ltd (Nasdaq: CMMB), a clinical-stage biotech firm, reported its financial and operational results for Q2 2021. As of June 30, 2021, the company had $67 million in cash, sufficient to fund operations into mid-2023. The company is advancing three Phase 2 trials for its lead product, CM-101, targeting fibrosis-related diseases. The ongoing SPRING and SPLASH trials are set to yield data in 2022. Despite rising R&D and administrative expenses totaling $2.8 million, Chemomab remains optimistic about its pipeline and collaborations, particularly with AGC Biologics.
FAQ
What is the current stock price of Chemomab Therapeutics (CMMB)?
What is the market cap of Chemomab Therapeutics (CMMB)?
